Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.2.815

Lung Cancer in Women, a Different Disease: Survival Differences by Sex in Turkey  

Ulas, Arife (Department of Medical Oncology, Ankara Ataturk Training and Research Hospital)
Tokluoglu, Saadet (Ankara Oncology Teaching and Research Hospital)
Kos, Mehmet (Department of Internal Medicine, Faculty of Medicine, Duzce University)
Silay, Kamile (Department of Internal Medicine and Geriatrics, Faculty of Medicine, Yildirim Beyazit University)
Akinci, Sema (Department of Hematology, Ankara Ataturk Training and Research Hospital)
Oksuzoglu, Berna (Ankara Oncology Teaching and Research Hospital)
Alkis, Necati (Ankara Oncology Teaching and Research Hospital)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.2, 2015 , pp. 815-822 More about this Journal
Abstract
Purpose: In this study, we aimed to evaluate the effects of sex-based non-small cell lung cancer (NSCLC) varieties on survival rates. Materials and Methods: A retrospective study was performed in patients with NSCLC who were diagnosed by histological methods between the years 2000 and 2010. A chi-square test was used to compare variables. Overall survival (OS) was estimated by the Kaplan-Meier method. Results: Of the 844 patients, 117 (13.9%) were women and 727 (86.1%) were men. Adenocarcinoma was more common in women than in men (p<0.0001). There were more women non-smokers than men (p<0.0001). There was no statistically significant difference in ECOG PS, weight loss>10%, stage, LDH, albumin and treatment between women and men. Women younger than 65 years (17.0 vs 12.0 months; p=0.03), who had adenocarcinoma histology (15.0 vs 10.0 months; p=0.006) and who had a hemoglobin level ${\geq}12g/dL$ (18.0 vs 12.0 months; p=0.01) were found to have a better median OS rate than men. Median OS rates were found to be 13.0 months in females and 12.0 months in males (p=0.14). Among metastatic patients, the median OS was 11.0 months in females and 8.0 months in males (p=0.005). Among stage IIIB and stage IV patients who had first line platinum-based chemotherapy, the median OS was 17.0 months in women and 11.0 months in men (p=0.002). The response rate of chemotherapy was higher in women than in men (p=0.03). Conclusions: In our study, we found that survival duration is longer and chemotherapy response is better in women with NSCLC who do not have anemia or comorbidities and who are mostly non-smokers with adenocarcinomas. Further studies regarding the causes of these differences may provide clarity on this subject.
Keywords
Non-small cell lung cancer; adenocarcinoma; sex differences; survival; Turkey;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Albain KS, Crowley JJ, LeBlanc M, et al (1991). Survival determinants in extensive-stage non small-cell lung cancer: the Southwest oncology group experience. J Clin Oncol, 9, 1618-26.
2 Babacan NA, Yucel B, Kilickap S, et al (2014). Lung cancer in women: a single institution experience with 50 patients. Asian Pac J Cancer Prev, 15, 151-4.   DOI   ScienceOn
3 Bain C, Feskanich D, Speicer FE, et al (2004). Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst, 96, 826-34.   DOI
4 Batevik R, Grong K, Segadal L, Stangeland L (2005). The female gender has a positive effect on survival independent of background life expectancy following surgical resection of primary non-small cell lung cancer: a study of absolute and relative survival over 15 years. Lung Cancer, 47, 173-81.   DOI
5 Caldarella A, Crocetti E, Comin CE (2007). Gender differences in non-small cell lung cancer: a population-based study. Eur J Surg Oncol, 33, 763-8.   DOI
6 Cerfolio RJ, Bryant AS, Scott E (2006). Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest, 130, 1796-802.   DOI
7 Chang JW, Asamura H, Kawachi R, Watanabe S (2009). Gender difference in survival of resected non-small cell lung cancer: histology-related phenomenon? J Thorac Cardiovasc Surg, 137, 807-12.   DOI
8 Chlebowski RT, Schwartz AG, Wakelee H, et al (2009). Oestrogen plus progestin and lung cancer in postmenopausal women (women's health initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet, 374, 1243-51.   DOI
9 Chollat-Traquet C (1992). Women and tobacco, world health organization, Geneva pp. 8, 203.
10 De Perrot M, Licker M, Bouchardy C, et al (2000). Sex differences in presentation, management, and prognosis of patients with nonsmall cell lung carcinoma. J Thorac Cardiovasc Surg, 119, 21-6.   DOI
11 Deleuran T, Thomsen RW, Norgaard M, et al (2013). Comorbidity and survival of danish lung cancer patients from 2000-2011: a population-based cohort study. Clin Epidemiol, 1, 31-8.
12 Devesa SS, Bray F, Vizcaino AP, Parkin DM (2005). International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer, 117, 294-9   DOI
13 Dresler C, Fratelli C, Babb J, et al (2000). Gender differences in genetic susceptibility to lung cancer. Lung Cancer, 30, 153-60.   DOI
14 Efficace F, Bottomley A, Smit EF, et al (2006). EORTC lung cancer group quality of life unit. is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? a multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol, 17, 1698-704.   DOI   ScienceOn
15 Goksel T, Akkoclu A (2002). Pattern of lung cancer in Turkey, 1994-1998. Turkish Thoracic Society, Lung and Pleural Malignancies Study Group. Respiration, 69, 207-10.   DOI
16 Ferrigno D, Buccheri G (2003). Hematologic counts and clinical correlates in 1201 newly diagnosed lung cancer patients. Monaldi Arch Chest Dis, 59, 193-8.
17 Finkelstein DM, Ettinger DS, Ruckdeschel JC (1986). Longterm survivors in metastatic non-small cell lung cancer: An Eastern Cooperative Oncology Group Study. J Clin Oncol, 4, 702-09.
18 Gasperina J, Rom W (2004). Gender and lung cancer. Clin Lung Cancer, 5, 353-9.   DOI
19 Gonlugur U, Gonlugur TE, Kaptanoglu M, et al (2008). The changing epidemiological trends for carcinoma of the lung in Turkey. Saudi Med J, 29, 749-53.
20 Nakamura H, Ando K, Shinmyo T, et al (2011). Female gender is an independent prognostic factor in non-small cell lung cancer: a meta-analysis. Ann Thorac Cardiovasc Surg, 17, 469-80.   DOI
21 Henschke CI, Yip R, Miettinen OS (2006). Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer. JAMA, 296, 180-4.   DOI
22 Kawai H, Tada A, Kawahara M, et al (2005). Japan national hospital study group for lung cancer. smoking history before surgery and prognosis in patients with stage IA non-small cell lung cancer-a multicenter study. Lung Cancer, 49, 63-70.   DOI
23 Keller SM, Vangel MG, Adak S, et al (2002). The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer. Lung Cancer, 37, 303-9.   DOI
24 Mok TS, Wu YL, Thongprasert S, et al (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361, 947-57.   DOI
25 Koyi H, Hillerdal G, Branden E (2002). A prospective study of total material of lung cancer from a county in Sweden 1997-1999; gender, symptoms, type, stage and smoking habits. Lung Cancer, 36, 9-14.   DOI
26 Kure EH, Ryberg D, Hewer A et al (1996). P53 mutations in lung tumours: relationship to gender and lung DNA adduct levels. Carcinogenesis, 17, 2201-5.   DOI
27 Miller VA, Kris MG, Shah N, et al (2004). Bronchiolo-alveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol, 22, 1103-9.   DOI
28 Mostertz W, Stevenson M, Acharya C, et al (2010). Age-and sex-specific genomic profiles in non-small cell lung cancer. JAMA, 303, 535-43.   DOI
29 North CM, Christiani DC (2013). Women and lung cancer: what is new? Semin Thorac Cardiovasc Surg, 25, 87-94.   DOI
30 Paesmans M, Sculier JP, Libert P, et al (1995). Prognostic factors for survival in advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol, 13, 1221-30.
31 Parente Lamelas I, Abal Arca J, Garcia Garcia MJ, et al (2011). Lung cancer in women: a comparison with men and an analysis of cases diagnosed in Ourense (Spain) 1999-2006. Arch Bronconeumol, 47, 61-5.
32 Patel J (2005). Lung cancer in women. J Clin Oncol, 23, 3212-8.   DOI
33 Risch HA, Howe GR, Jain M, et al (1993). Are female smokers at higher risk for lung cancer than male smokers? A casecontrol analysis by histologic type. Am J Epidemiol, 138, 281-93.
34 Pinsky PF, Church TR, Izmirlian G, Kramer BS (2013). The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer, 119, 3976-83.   DOI
35 Pitz MW, Musto G, Navaratnam S (2013). Sex as an independent prognostic factor in a population based, non-small cell lung cancer cohort. Can Respir J, 20, 30-4.   DOI
36 Radzikowska E, Glaz P, Roszkowski K (2002). Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20, 561 cases. Ann Oncol, 13, 1087-93.   DOI
37 Sculier JP, Chansky K, Crowley JJ, et al (2008). International staging committee participating institutions. the impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol, 3, 457-66.   DOI   ScienceOn
38 Sekine A, Satoh H, Iwasawa T, et al (2014). Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy. Med Oncol, 3, 228-34.
39 Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al (2005). Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 353, 123-32.   DOI
40 Shriver SP , Bourdeau HA, Gubish CT, et al. (2000). Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer. J Natl Cancer Inst, 92, 24-33.   DOI
41 Taioli E, Wynder EL (1994). Re: endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst, 86, 869-70.   DOI
42 Siegel R, Ma J, Zou Z, Jemal A (2014). Cancer statistics, 2014. CA Cancer J Clin, 64, 9-29.   DOI
43 Subramanian J, Morgensztern D, Goodgame B, et al. (2010). Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis. J Thorac Oncol, 5, 23-8.   DOI
44 Sun S, Schiller JH, Gazdar AK (2007). Lung cancer in never smokers-a different disease. Nat Rev Cancer, 7, 778-90.   DOI
45 Thomas L, Doyle L, Edelman M (2005). Lung cancer in women: emerging differences in epidemiology, biology and therapy. Chest, 128, 370-81.   DOI
46 Travis WD, Brambilla E, Muller-Hermlink HK, Harris CC (eds). (2004). World health organization classification of tumours. pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC Press, Lyon.
47 Travis WD, Lubin J, Ries L, Devesa S (1996). United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. Cancer, 77, 2464-70.   DOI
48 Visbal AL, Williams BA, Nichols FC 3rd, et al (2004). Gender differences in non-small cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg, 78, 209-15.   DOI
49 Wakelee HA, Chang ET, Gomez SL, et al (2007). Lung cancer incidence in never smokers. J Clin Oncol, 25, 472-8.   DOI
50 Wakelee HA, Wang W, Schiller JH, et al (2006). Eastern Cooperative Oncology Group. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol, 1, 441-6.   DOI
51 Wheatley-Price P, Blackhall F, Lee SM, et al (2010). The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. Ann Oncol, 21, 2023-8.   DOI
52 Yang SY, Yang TY, Chen KC, et al (2011). EGFR L858R mutation and polymorphisms of genes related to estrogen biosynthesis and metabolism in never-smoking female lung adenocarcinoma patients. Clin Cancer Res, 17, 2149-58.   DOI
53 Yano T, Miura N, Takenaka T, et al (2008). Never-smoking nonsmall cell lung cancer as a separate entity: clinicopathologic features and survival. Cancer, 113, 1012-8.   DOI
54 Yoshino I, Kawano D, Oba T, et al 2006). Smoking status as a prognostic factor in patients with stage I pulmonary adenocarcinoma. Ann Thorac Surg, 81, 1189-93.   DOI